Dr Agarwals Health Care Ltd Q4 FY26 Earnings Analysis

- Dr. Agarwal’s Health Care Limited plans to add 55 to 60 new facilities annually, aiming to increase network size by roughly 20% each year. - Same-store sales growth is strong, exceeding 13.5%, reflecting healthy organic growth. - Surgical services continue to be the main revenue driver, with 67% contribution to group revenue. - High-end cataract surgeries contribute around 28% of overall cataract surgery revenue, indicating premiumization. - Volume growth and value growth both contribute approximately equally (~6.5% each) to overall growth. - Newer centers take about 15-18 months to break even, while core market facilities break even in 6-7 months, averaging about 12 months overall. - Continued adoption of advanced technologies like robotic and Femto cataract surgeries supports premiumization and value growth. - The company expects robust revenue growth through a combination of new facility additions, premiumization, and volume increases across regions.

- The company aims to add 55 to 60 new facilities annually, expanding its network by about 20% each year, supporting revenue growth. - Facilities in core markets breakeven within 6-7 months; newer regions take 15-18 months; blended average breakeven within 12 months, enhancing profitability. - Same-store sales growth is strong at 13.5%, indicating healthy organic growth. - EBITDA margins have been maintained at approximately 28.4%-28.5% despite rapid expansion, suggesting operational efficiency. - Profit After Tax (PAT) grew 74.3% YoY to Rs. 118 crores with margin expansion of 234 basis points, demonstrating improving profitability. - Operating cash flow averages 80%, supporting sustainable operations and funding expansion. - Completion of merger by Q3-Q4 FY2027 is expected, potentially streamlining operations and cost synergies. - Expansion into new markets and premiumization contribute to higher value growth, supporting sustained earnings growth.

- Annual addition of 55 to 60 new facilities planned, with network growth targeted at ~20% per year. - CAPEX per facility type: - Surgical secondary facility: Rs. 5.5 to 6 crores - Tertiary facility: Rs. 11 to 12 crores - Primary facility: ~Rs. 35 lakhs - Ethiopia subsidiary: Exploring entry with organic growth; feasibility study ongoing with no CAPEX estimates yet; funding fully by Orbit entity. - Subsidiary facility (Cathedral Road): CAPEX spend Rs. 35 crores out of Rs. 70 crores committed; licensing and approvals expected by Q2 FY2027. - Merger process ongoing with expected completion by Q3/Q4 2027. - Total YTD CAPEX about Rs. 275 crores out of Rs. 310 crores committed for the year.

- No specific mention of current or future fundraising through debt or equity in the provided transcript. - The company has repaid INR95 crores in loans from IPO proceeds, leading to lower finance costs and higher profitability, indicating a focus on reducing debt rather than raising new debt. - CAPEX for the year is around Rs.275 crores out of the committed Rs.310 crores, with no explicit mention of financing sources beyond using operating cash flows and IPO proceeds. - Expansion plans include adding 55-60 new facilities yearly, but funding is implied to come from healthy operating cash flows and internal accruals rather than external fundraising. - No explicit update on plans for equity fundraising or new debt issuance mentioned in the call transcript.

The transcript does not explicitly mention any current or expected order book or pending orders details for Dr. Agarwal’s Health Care Limited. However, related business and expansion updates include: - Planned addition of 55 to 60 new facilities every year. - 38 new facilities added up to December 2025, including 23 surgical centers. - Additional 16 centers planned in the next quarter, with 11 surgical centers. - Focus on increasing network size by about 20% annually. - Facilities in core markets breakeven within 6-7 months; newer regions take 15-18 months. - Merger process expected to complete by Q3/Q4 FY2027. - New facility licenses expected by end of Q2 FY2027 for subsidiary. - CAPEX commitments ongoing, with Rs.275 crores spent out of Rs.310 crores committed YTD. No direct reference to "order book" or "pending orders" is provided.